Document Detail


Intracellular oxidative activity and respiratory burst of leukocytes isolated from multiple sclerosis patients.
MedLine Citation:
PMID:  16263194     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Oxidative damage induced by free radicals and reactive oxygen species (ROS) have been suggested to play an important role in the development of autoimmune diseases such as multiple sclerosis (MS) disease and it has been hypothesised that oxidative injury could mediate demyelination and axonal injury in MS subjects. In our study, we compared intracellular oxidative activity and the respiratory burst activity in MS patients (n=20) and healthy controls (n=15) using leukocytes as cellular model. At this purpose, intracellular ROS levels were evaluated by fluorometric assay using the 2'-7'-dichlorodihydrofluorescin diacetate probe (H(2)DCFDA) in untreated or in leukocytes stimulated with phorbol-12-myristate-13-acetate (PMA). Our results demonstrate that the intracellular spontaneous ROS production in leukocytes from MS patients was higher with respect to cells from control subjects (p<0.001). PMA addition induced a higher formation of ROS both in leukocytes from MS patients and controls (p<0.001). The PMA-induced production of ROS was significantly higher in leukocytes from MS with respect to controls (p<0.001). Significant positive correlations were established between intracellular spontaneous or PMA-induced production of ROS in leukocytes isolated from MS patients and the clinical parameters used to evaluate disease disability such as expanded disability status scale (EDSS), brain lesions evaluated by MRI and visual evoked potential (VEP) (p<0.001). In conclusion, our results demonstrate higher levels of intracellular ROS in untreated or in PMA-treated leukocytes isolated from MS patients with respect to healthy subjects confirming the role of oxidative stress in multiple sclerosis.
Authors:
G Ferretti; T Bacchetti; F DiLudovico; B Viti; V A Angeleri; M Danni; L Provinciali
Related Documents :
1703854 - Hla-antigen frequencies in patients with progressive systemic sclerosis and morphea.
20032564 - Clinical characteristics of defecation syncope compared with micturition syncope.
12910434 - Glatiramer acetate treatment in patients with childhood and juvenile onset multiple scl...
18280504 - The dymus questionnaire for the assessment of dysphagia in multiple sclerosis.
18619774 - Optional filters in trauma patients: can retrieval rates be improved?
3087714 - Total parenteral nutrition needs in different types of short bowel syndrome.
Publication Detail:
Type:  Journal Article     Date:  2005-11-02
Journal Detail:
Title:  Neurochemistry international     Volume:  48     ISSN:  0197-0186     ISO Abbreviation:  Neurochem. Int.     Publication Date:  2006 Jan 
Date Detail:
Created Date:  2005-12-30     Completed Date:  2006-04-24     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8006959     Medline TA:  Neurochem Int     Country:  England    
Other Details:
Languages:  eng     Pagination:  87-92     Citation Subset:  IM    
Affiliation:
Istituto di Biochimica, Facoltà di Medicina e Chirurgia, Università Politecnica delle Marche, Via Ranieri, 60131 Ancona, Italy. g.ferretti@univpm.it
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Case-Control Studies
Evoked Potentials, Visual
Female
Fluoresceins / chemistry
Fluorescent Dyes / chemistry
Humans
Leukocytes / drug effects,  metabolism*
Magnetic Resonance Imaging
Male
Middle Aged
Multiple Sclerosis / blood*,  metabolism,  physiopathology
Oxidative Stress*
Respiratory Burst
Tetradecanoylphorbol Acetate / pharmacology
Chemical
Reg. No./Substance:
0/Fluoresceins; 0/Fluorescent Dyes; 106070-31-9/2',7'-dichlorodihydrofluorescein; 16561-29-8/Tetradecanoylphorbol Acetate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Intraocular sustained drug delivery using implantable polymeric devices.
Next Document:  Synthesis of new hexahydro- and octahydropyrido[1,2-c]pyrimidine derivatives with an arylpiperazine ...